BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 49.12 million. The enterprise value is 2.10 million.

Market Cap	49.12M
Enterprise Value	2.10M

Important Dates

The last earnings date was Sunday, May 25, 2025.

Earnings Date	May 25, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 47.46% in one year.

Current Share Class	2.23B
Shares Outstanding	2.23B
Shares Change (YoY)	+47.46%
Shares Change (QoQ)	+69.54%
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	3.73%
Float	2.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.59
PB Ratio	0.63
P/TBV Ratio	1.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.17
EV / Sales	0.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.02

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.66.

Current Ratio	2.27
Quick Ratio	2.02
Debt / Equity	0.66
Debt / EBITDA	n/a
Debt / FCF	-0.42
Interest Coverage	-1.95

Financial Efficiency

Return on equity (ROE) is -20.03% and return on invested capital (ROIC) is -35.44%.

Return on Equity (ROE)	-20.03%
Return on Assets (ROA)	-21.98%
Return on Invested Capital (ROIC)	-35.44%
Return on Capital Employed (ROCE)	-56.72%
Revenue Per Employee	2.97M
Profits Per Employee	-451,873
Employee Count	28
Asset Turnover	0.47
Inventory Turnover	2.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.57% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	-87.57%
50-Day Moving Average	1.89
200-Day Moving Average	6.52
Relative Strength Index (RSI)	61.21
Average Volume (20 Days)	5,145,729

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 83.18 million and -12.65 million in losses. Loss per share was -0.01.

Revenue	83.18M
Gross Profit	53.98M
Operating Income	-62.26M
Pretax Income	-12.65M
Net Income	-12.65M
EBITDA	-52.13M
EBIT	-62.26M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 98.18 million in cash and 51.17 million in debt, giving a net cash position of 47.02 million or 0.02 per share.

Cash & Cash Equivalents	98.18M
Total Debt	51.17M
Net Cash	47.02M
Net Cash Per Share	0.02
Equity (Book Value)	77.68M
Book Value Per Share	0.03
Working Capital	66.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -120.47 million and capital expenditures -78,194, giving a free cash flow of -120.55 million.

Operating Cash Flow	-120.47M
Capital Expenditures	-78,194
Free Cash Flow	-120.55M
FCF Per Share	-0.05

Full Cash Flow Statement

Margins

Gross margin is 64.90%, with operating and profit margins of -74.85% and -15.21%.

Gross Margin	64.90%
Operating Margin	-74.85%
Pretax Margin	-15.21%
Profit Margin	-15.21%
EBITDA Margin	-62.67%
EBIT Margin	-74.85%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-47.46%
Shareholder Yield	n/a
Earnings Yield	-25.76%
FCF Yield	-245.44%

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -11.89. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.89
Piotroski F-Score	n/a